Nyxoah SA NYXH
0.81 USD -0.05 (-5.63%)
At closeNov 5, 2026, 4:41 PM EST
0.82 +0.01 +1.11%
After hours · Nov 5, 4:41 PM ET
0.8001 Day range 0.88
0.80 52-week range 5.92
- YTD
- -82.37%
- 1 year
- -83.75%
- Market cap
- 82.59M
- Revenue (ttm)
- 5.08M
- EPS (ttm)
- -2.37
- Shares out
- 37.43M
- Forward P/E
- -5.03
- YTD return
- -82.37%
- 1-year return
- -83.75%
- Volume
- 213.36K
- Avg volume
- 310.27K
- Open
- 0.88
- Previous close
- 0.8594
- Day's range
- 0.8001 – 0.88
- 52-week range
- 0.80 – 5.92
- Beta
- 0.55
- Analysts
- Buy
- Price target
- 15.60 (+1823.5%)
- Earnings date
- Aug 6, 2024
1D +0.0127 (+1.48%)
Key statistics
- Enterprise value
- 227.81M
- PEG ratio
- 0.00
- Price / sales
- 59.68
- Price / book
- 2.63
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 29.70%
- Free cash flow
- -35.99M
- Total cash
- 70.98M
- Total debt
- 23.33M
- Return on equity
- -49.69%
- Short % of float
- 0.32%
- 50-day average
- 8.73
- 200-day average
- 9.37
Analyst view
Consensus: buy
Buy
Price target (mean) 15.60 +1823.5% upside
Now 0.811
- Target (low)
- 12.61
- Target (mean)
- 15.60
- Target (high)
- 17.46
Ratings (0m) 6 5 buy · 1 hold · 0 sell
- Strong buy2
- Buy3
- Hold1
- Sell0
- Strong sell0
Next earnings
Aug 6, 2024
Expected Aug 6, 2024. Consensus EPS estimate -0.4384.
Financials — quick view
NYXH Revenue — quarterly 7.67M
NYXH Net income — quarterly -32.96M
NYXH EPS — quarterly -0.578
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | -0.46 | -0.55 | -0.09 | -19.57% |
| Aug 6, 2024 | Jun 1, 2024 | -0.45 | — | — | — |
| Aug 6, 2024 | Jun 1, 2024 | -0.45 | -0.46 | -0.01 | -2.22% |
| May 14, 2024 | Mar 1, 2024 | -0.45 | -0.45 | 0.00 | 0.00% |
| May 14, 2024 | Mar 1, 2024 | -0.45 | — | — | — |
| Mar 5, 2024 | Dec 1, 2023 | -0.41 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 5, 2024 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Oct 11, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Sep 30, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 7, 2024 | Cantor Fitzgerald | main | Overweight | Overweight |
| Aug 7, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Nyxoah SA
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- Belgium
- Website
- nyxoah.com
News
Nyxoah Q3 2026 Earnings Call Transcript 
Nyxoah Q3 EPS $(0.20) Beats $(0.24) Estimate, Sales $10.554M Miss $11.110M Estimate 
Cantor Fitzgerald Maintains Overweight on Nyxoah, Lowers Price Target to $3 
Nyxoah to Release Third Quarter 2026 Financial Results on November 5, 2026 
Why RingCentral Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket 
Here's Why Nyxoah (NYXH) Could be Great Choice for a Bottom Fisher 
Nyxoah Reports Preliminary Q3 Global Net Sales Of ~€9.2M, Up 19% QoQ; Lowers FY26 Global Net Sales From €36M-€40M To €33M-€35M 
Nyxoah Announces Preliminary Results for the Third Quarter of 2026 and Adjusts Revenue Guidance for 2026 
Contrasting Nephros (NASDAQ:NEPH) & Nyxoah (NASDAQ:NYXH) 
Nyxoah: Label Expansion Set To Unlock A Monopoly In A Billion Dollar Market.
Your note
Sign in to keep a note on NYXH — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 4.99% | 1,715,125 | 13.72M | Sep 29, 2024 |
| Blackrock Inc. | 3.45% | 1,186,093 | 9.49M | Sep 29, 2024 |
| Franklin Resources, Inc. | 0.85% | 292,570 | 2.34M | Sep 29, 2024 |
| Millennium Management Llc | 0.55% | 187,367 | 1.50M | Sep 29, 2024 |
| CVI Holdings, LLC | 0.53% | 183,590 | 1.47M | Jun 29, 2024 |
| AXA S.A. | 0.44% | 152,000 | 1.22M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Small Cap Growth Fund | 1.94% | 667,557 | 5.34M | Aug 30, 2024 |
| BlackRock Health Sciences Term Trust | 1.89% | 648,041 | 5.18M | Sep 29, 2024 |
| Fidelity Select Portfolios - Pharmaceuticals | 1.39% | 479,065 | 3.83M | Oct 30, 2024 |
| Blackrock Funds-Health Sciences Opportunity Portfolio | 1.20% | 411,250 | 3.29M | Aug 30, 2024 |
| Fidelity Central Investment Port-International Equity Central Fd | 0.98% | 335,700 | 2.69M | Sep 29, 2024 |
| Putnam Fds Tr-Putnam Multi Cap Core Fd | 0.82% | 282,458 | 2.26M | Jul 30, 2024 |